New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
05:35 EDTNSRGY, VRX, LRLCYNestle creates Nestle Skin Health with acquisition of Valeant assets for $1.4B
Nestlé (NSRGY) announced it would extend its activities to include the field of specialized medical skin treatments through the creation of Nestlé Skin Health S.A. The foundation for the company would be Galderma, the 50/50 joint venture with L'Oreal (LRLCY), which would become fully-owned by Nestlé. Bübchen, the company's existing infant skin care business would be merged into the new entity. The acquisition of Galderma is awaiting final regulatory clearance. Nestlé is announcing it will reinforce Nestlé Skin Health with the acquisition from the Canadian firm Valeant Pharmaceuticals (VRX) of the full rights to commercialize several key aesthetic dermatology products in the U.S. and Canada for $1.4B in cash. The two markets together represent more than half of the fast-growing medical aesthetics market around the world. Galderma already commercializes the products included in this transaction outside those markets. Nestlé is acquiring the full rights to commercialize in the U.S. and Canada Restylane, Perlane and Emervel, products used for corrective facial aesthetic treatments, and Dysport, an aesthetic dermatology treatment. It will also acquire the full rights to Sculptra, a unique treatment for aesthetic and medical uses in the U.S., Canada and many markets around the world.
News For NSRGY;VRX;LRLCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 21, 2014
06:33 EDTVRXValeant price target raised to $182 from $167 at Cantor
Subscribe for More Information
October 20, 2014
12:23 EDTVRXAllergan holder Paulson encourages deal with Shire, Reuters says
Subscribe for More Information
09:25 EDTVRXValeant says talks to Ackman 'frequently'
Subscribe for More Information
09:08 EDTVRXValeant says not planning to walk away from Allergan deal before Dec. 18
Subscribe for More Information
08:58 EDTVRXValeant says still willing to improve bid for Allergan
Valeant (VRX) said would raise Allergan (AGN) bid "when time is right." Says hopes Allergan shareholders see that Valeant's operating model does work and will continue to work. Says Valeant (VRX), Allergan have "unique" business overlap. Says company "should" own Allergan. Says interests with Pershing, Ackman "aligned" on Allergan.
08:37 EDTVRXValeant says 'completely focused' on Allergan acquisition
Subscribe for More Information
07:34 EDTVRXValeant says remains focused on completing Allergan transaction
Subscribe for More Information
07:32 EDTVRXValeant narrows FY14 revenue view to $8.1B-$8.3B from $8B-$8.3B
Subscribe for More Information
07:30 EDTVRXValeant CEO says 'can bid more than anyone' in financially sound Allergan deal
Pearson says "we cannot stop" another company from making a bid that does not make economic sense, but he believes Valeant (VRX) can "bid more than anyone" for Allergan (AGN) in a deal that makes financial sense. Pearson says he has met with doctor groups and that 95% of those he's spoken with support Valeant's bid for Allergan. Valeant CEO J. Michael Pearson spoke on CNBC.
07:28 EDTVRXValeant raises FY14 cash EPS to $8.22-8.32 from $7.90-$8.10
Subscribe for More Information
07:06 EDTVRXValeant raises FY15 outlook cash EPS $10.00 from $9.90
Subscribe for More Information
07:05 EDTVRXValeant raises Q4 cash EPS $2.45-$2.55 from $2.35-$2.45
Subscribe for More Information
07:03 EDTVRXValeant reports Q3 cash EPS $2.11, Q3 GAAP EPS 81c
Reports Q3 revenue revenue $2.1B; Reports Q3 total same store sales organic growth 19%. Bausch + Lomb organic growth was 12%. Q3 GAAP Operating Cash Flow $619 million, an increase of 207%; Adjusted Operating Cash Flow $771 million, an increase of 89%
October 17, 2014
09:47 EDTVRXValeant will not raise Allergan bid ahead of record date, CNBC reports
Valeant (VRX) will not raise its hostile takeover bid for Allergan (AGN) ahead of the record date for the vote, CNBC's David Faber reports. Allergan (AGN) is not currently in takeover talks with Actavis (ACT), Faber added.
09:43 EDTVRXValeant not going to raise Allergan bid ahead of meeting, CNBC reports
Subscribe for More Information
October 16, 2014
12:42 EDTVRXAckman believes Allergan, Valeant merger likely, CNBC reports
Subscribe for More Information
12:38 EDTVRXAckman says Allergan CEO manipulated Valeant shares, CNBC reports
Subscribe for More Information
05:29 EDTNSRGYNestle reports FY outlook unchanged
Subscribe for More Information
05:28 EDTNSRGYNestle reports 9 month sales of CHF 66.2B
Subscribe for More Information
October 15, 2014
13:07 EDTVRXAllergan seeing arb-related selling pressure, says BMO Capital
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use